You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSertraline
Accession NumberDB01104  (APRD00175)
TypeSmall Molecule
GroupsApproved
DescriptionSertraline hydrochloride belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache (see Toxicity section below for a more detailed listing of side effects). Compared to other agents in this class, sertraline may cause greater diarrheal and male sexual dysfunction effects. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Sertraline may be used to treat major depressive disorder, obsessive-compulsive disorder (OCD), panic disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD) and social anxiety disorder (social phobia).
Structure
Thumb
Synonyms
(+)-Sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S,4S)-Sertraline
cis-(+)-Sertraline
CP 51974
Sertralina
Sertraline
Sertralinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act SertralineCapsule25 mgOralActavis Pharma Company2006-11-08Not applicableCanada
Act SertralineCapsule50 mgOralActavis Pharma Company2006-11-08Not applicableCanada
Act SertralineCapsule100 mgOralActavis Pharma Company2006-11-08Not applicableCanada
Auro-sertralineCapsule100 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-sertralineCapsule25 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Auro-sertralineCapsule50 mgOralAuro Pharma Inc2012-10-18Not applicableCanada
Bio-sertralineCapsule50 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-sertralineCapsule100 mgOralBiomed PharmaNot applicableNot applicableCanada
Bio-sertralineCapsule25 mgOralBiomed PharmaNot applicableNot applicableCanada
Dom-sertralineCapsule25 mgOralDominion Pharmacal2002-05-31Not applicableCanada
Dom-sertralineCapsule50 mgOralDominion Pharmacal2002-05-31Not applicableCanada
Dom-sertralineCapsule100 mgOralDominion Pharmacal2002-05-31Not applicableCanada
Gd-sertralineCapsule25 mgOralGenmed A Division Of Pfizer Canada Inc2010-11-112016-05-31Canada
Gd-sertralineCapsule50 mgOralGenmed A Division Of Pfizer Canada Inc2010-11-112016-05-31Canada
Gd-sertralineCapsule100 mgOralGenmed A Division Of Pfizer Canada Inc2010-11-112016-05-31Canada
Ipg-sertralineCapsule25 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-sertralineCapsule50 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-sertralineCapsule100 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-sertralineCapsule25 mgOralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-sertralineCapsule50 mgOralJamp Pharma Corporation2011-10-06Not applicableCanada
Jamp-sertralineCapsule100 mgOralJamp Pharma Corporation2011-10-06Not applicableCanada
Mar-sertralineCapsule25 mgOralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mar-sertralineCapsule50 mgOralMarcan Pharmaceuticals Inc2014-01-06Not applicableCanada
Mar-sertralineCapsule100 mgOralMarcan Pharmaceuticals Inc2014-01-16Not applicableCanada
Mint-sertralineCapsule25 mgOralMint Pharmaceuticals Inc2013-04-29Not applicableCanada
Mint-sertralineCapsule50 mgOralMint Pharmaceuticals Inc2013-04-29Not applicableCanada
Mint-sertralineCapsule100 mgOralMint Pharmaceuticals Inc2013-04-29Not applicableCanada
Mylan-sertralineCapsule100 mgOralMylan Pharmaceuticals Ulc2000-07-24Not applicableCanada
Mylan-sertralineCapsule25 mgOralMylan Pharmaceuticals Ulc2000-07-24Not applicableCanada
Mylan-sertralineCapsule50 mgOralMylan Pharmaceuticals Ulc2000-07-24Not applicableCanada
Nu-sertraline CapsulesCapsule100 mgOralNu Pharm Inc2003-06-272012-09-04Canada
Nu-sertraline CapsulesCapsule25 mgOralNu Pharm Inc2003-06-272012-09-04Canada
Nu-sertraline CapsulesCapsule50 mgOralNu Pharm Inc2003-06-272012-09-04Canada
PHL-sertralineCapsule50 mgOralPharmel Inc2002-05-31Not applicableCanada
PHL-sertralineCapsule100 mgOralPharmel Inc2002-05-31Not applicableCanada
PHL-sertralineCapsule25 mgOralPharmel Inc2002-05-31Not applicableCanada
PMS-sertralineCapsule25 mgOralPharmascience Inc2002-01-30Not applicableCanada
PMS-sertralineCapsule50 mgOralPharmascience Inc2002-01-30Not applicableCanada
PMS-sertralineCapsule100 mgOralPharmascience Inc2002-01-30Not applicableCanada
Priva-sertralineCapsule100 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-sertralineCapsule25 mgOralPharmapar IncNot applicableNot applicableCanada
Priva-sertralineCapsule50 mgOralPharmapar IncNot applicableNot applicableCanada
Q-sertralineCapsule25 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-sertralineCapsule50 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Q-sertralineCapsule100 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ran-sertralineCapsule25 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-11-24Not applicableCanada
Ran-sertralineCapsule50 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-11-24Not applicableCanada
Ran-sertralineCapsule100 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-11-24Not applicableCanada
Ratio-sertralineCapsule50 mgOralRatiopharm Inc Division Of Teva Canada Limited2002-07-052014-09-24Canada
Ratio-sertralineCapsule100 mgOralRatiopharm Inc Division Of Teva Canada Limited2002-07-052014-09-19Canada
Ratio-sertralineCapsule25 mgOralRatiopharm Inc Division Of Teva Canada Limited2002-07-052014-09-19Canada
Riva-sertralineCapsule100 mgOralLaboratoire Riva Inc2005-01-10Not applicableCanada
Riva-sertralineCapsule25 mgOralLaboratoire Riva Inc2005-01-10Not applicableCanada
Riva-sertralineCapsule50 mgOralLaboratoire Riva Inc2005-10-01Not applicableCanada
Sandoz SertralineCapsule25 mgOralSandoz Canada Incorporated2002-02-13Not applicableCanada
Sandoz SertralineCapsule50 mgOralSandoz Canada Incorporated2002-02-13Not applicableCanada
Sandoz SertralineCapsule100 mgOralSandoz Canada Incorporated2002-02-13Not applicableCanada
SertralineCapsule50 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
SertralineCapsule50 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
SertralineCapsule25 mgOralMeliapharm Inc2010-10-122014-06-25Canada
SertralineCapsule25 mgOralSanis Health Inc2010-08-03Not applicableCanada
SertralineCapsule25 mgOralSanis Health Inc2009-10-222010-06-08Canada
SertralineCapsule100 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
SertralineCapsule100 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
SertralineCapsule50 mgOralMeliapharm Inc2010-10-122014-06-25Canada
SertralineCapsule50 mgOralSanis Health Inc2010-08-03Not applicableCanada
SertralineCapsule50 mgOralSanis Health Inc2009-10-222010-06-08Canada
SertralineCapsule100 mgOralMeliapharm Inc2010-10-122014-06-25Canada
SertralineCapsule100 mgOralSanis Health Inc2010-08-03Not applicableCanada
SertralineCapsule25 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
SertralineCapsule25 mgOralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
SertralineCapsule100 mgOralSanis Health Inc2009-10-222010-06-08Canada
Sertraline HydrochlorideTablet, film coated100 mg/1OralCardinal Health1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-19Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralContract Pharmacy Services Pa2010-03-15Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralGreenstone LLC1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralKAISER FOUNDATION HOSPITALS2012-01-06Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralPhysicians Total Care, Inc.2006-08-24Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-05-13Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralGreenstone LLC1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralPhysicians Total Care, Inc.2006-08-16Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline HydrochlorideSolution, concentrate20 mg/mLOralGreenstone LLC1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralREMEDYREPACK INC.2016-05-19Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralCardinal Health1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralPhysicians Total Care, Inc.2006-09-12Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralLife Line Home Care Services1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralGreenstone LLC1992-02-11Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-07Not applicableUs
Sertraline-100Capsule100.0 mgOralPro Doc Limitee2001-02-15Not applicableCanada
Sertraline-25Capsule25.0 mgOralPro Doc Limitee2001-02-15Not applicableCanada
Sertraline-50Capsule50.0 mgOralPro Doc Limitee2001-02-15Not applicableCanada
Teva-sertralineCapsule100 mgOralTeva Canada Limited1999-08-16Not applicableCanada
Teva-sertralineCapsule50 mgOralTeva Canada Limited1999-08-16Not applicableCanada
Teva-sertralineCapsule25 mgOralTeva Canada Limited1999-08-16Not applicableCanada
Van-sertralineCapsule25 mgOralVanc Pharmaceuticals Inc2015-06-10Not applicableCanada
Van-sertralineCapsule50 mgOralVanc Pharmaceuticals Inc2015-06-10Not applicableCanada
Van-sertralineCapsule100 mgOralVanc Pharmaceuticals Inc2015-06-10Not applicableCanada
ZoloftTablet, film coated100 mg/1OralREMEDYREPACK INC.2013-02-25Not applicableUs
ZoloftTablet, film coated50 mg/1OralRoerig1992-02-11Not applicableUs
ZoloftTablet, film coated50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
ZoloftTablet, film coated50 mg/1OralCardinal Health1992-02-11Not applicableUs
ZoloftTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc1992-02-11Not applicableUs
ZoloftTablet, film coated100 mg/1OralRoerig1992-02-11Not applicableUs
ZoloftTablet, film coated100 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2012-04-03Not applicableUs
ZoloftTablet, film coated50 mg/1OralSTAT Rx USA LLC1992-02-11Not applicableUs
ZoloftTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc1992-02-11Not applicableUs
ZoloftSolution, concentrate20 mg/mLOralRoerig1992-02-11Not applicableUs
ZoloftCapsule25 mgOralPfizer Canada Inc1995-12-31Not applicableCanada
ZoloftTablet, film coated100 mg/1OralSTAT Rx USA LLC1992-02-11Not applicableUs
ZoloftTablet, film coated50 mg/1OralPd Rx Pharmaceuticals, Inc.1992-02-11Not applicableUs
ZoloftTablet, film coated25 mg/1OralRoerig1992-02-11Not applicableUs
Zoloft Cap 100mgCapsule100 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Zoloft Cap 50mgCapsule50 mgOralPfizer Canada Inc1992-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-sertralineCapsule100 mgOralApotex Inc1999-09-01Not applicableCanada
Apo-sertralineCapsule25 mgOralApotex Inc1999-09-01Not applicableCanada
Apo-sertralineCapsule50 mgOralApotex Inc1999-09-01Not applicableCanada
SertralineTablet, film coated50 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-08-20Not applicableUs
SertralineTablet100 mg/1OralDIRECT RX2014-01-01Not applicableUs
SertralineTablet, film coated100 mg/1OralLupin Pharmaceuticals, Inc.2007-02-06Not applicableUs
SertralineTablet, film coated50 mg/1OralExelan Pharmaceuticals, Inc.2012-08-20Not applicableUs
SertralineTablet, film coated100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-06Not applicableUs
SertralineTablet, film coated50 mg/1OralLUPIN LIMITED2007-02-06Not applicableUs
SertralineTablet100 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-18Not applicableUs
SertralineTablet, film coated25 mg/1OralProficient Rx LP2007-02-06Not applicableUs
SertralineTablet, film coated50 mg/1OralClinical Solutions Wholesale2007-02-06Not applicableUs
SertralineTablet, film coated50 mg/1OralWest ward Pharmaceutical Corp2012-11-06Not applicableUs
SertralineTablet, film coated100 mg/1OralREMEDYREPACK INC.2015-04-14Not applicableUs
SertralineTablet50 mg/1OralDIRECT RX2014-01-01Not applicableUs
SertralineTablet, film coated50 mg/1OralNorthwind Pharmaceuticals, LLC2014-07-11Not applicableUs
SertralineTablet, film coated100 mg/1OralExelan Pharmaceuticals, Inc.2012-08-20Not applicableUs
SertralineTablet50 mg/1OralCardinal Health2013-07-05Not applicableUs
SertralineTablet50 mg/1OralInternational Labs, Inc.2012-02-202016-10-13Us
SertralineTablet, film coated100 mg/1OralLUPIN LIMITED2007-02-06Not applicableUs
SertralineTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-08-20Not applicableUs
SertralineTablet, film coated100 mg/1OralClinical Solutions Wholesale2007-02-06Not applicableUs
SertralineTablet50 mg/1OralNorthwind Pharmaceuticals, LLC2016-11-11Not applicableUs
SertralineTablet, film coated25 mg/1OralWest ward Pharmaceutical Corp2012-11-06Not applicableUs
SertralineTablet, film coated100 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
SertralineTablet, film coated25 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-06Not applicableUs
SertralineTablet25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-18Not applicableUs
SertralineTablet25 mg/1OralCardinal Health2013-07-05Not applicableUs
SertralineTablet, film coated50 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
SertralineTablet, film coated100 mg/1OralNorthwind Pharmaceuticals2014-05-27Not applicableUs
SertralineTablet, film coated50 mg/1OralProficient Rx LP2007-02-06Not applicableUs
SertralineTablet, film coated25 mg/1OralTYA Pharmaceuticals2007-02-06Not applicableUs
SertralineTablet, film coated25 mg/1OralLupin Pharmaceuticals, Inc.2007-02-06Not applicableUs
SertralineTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-06Not applicableUs
SertralineTablet, film coated25 mg/1OralAphena Pharma Solutions Tennessee, Llc2012-08-20Not applicableUs
SertralineTablet, film coated25 mg/1OralLUPIN LIMITED2007-02-06Not applicableUs
SertralineTablet50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-12-18Not applicableUs
SertralineTablet, film coated25 mg/1OralClinical Solutions Wholesale2007-02-06Not applicableUs
SertralineTablet100 mg/1OralCardinal Health2010-12-15Not applicableUs
SertralineTablet, film coated100 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
SertralineTablet, film coated100 mg/1OralWest ward Pharmaceutical Corp2012-11-06Not applicableUs
SertralineTablet, film coated100 mg/1OralProficient Rx LP2007-02-06Not applicableUs
SertralineTablet, film coated100 mg/1OralAidarex Pharmaceuticals LLC2007-02-06Not applicableUs
SertralineTablet, film coated50 mg/1OralReady Meds2012-11-06Not applicableUs
SertralineTablet, film coated50 mg/1OralLupin Pharmaceuticals, Inc.2007-02-06Not applicableUs
SertralineTablet, film coated25 mg/1OralExelan Pharmaceuticals, Inc.2012-08-20Not applicableUs
SertralineTablet, film coated50 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralMylan Pharmaceuticals Inc.2013-05-29Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-03-282016-10-21Us
Sertraline HydrochlorideTablet, film coated100 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, coated100 mg/1OralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralMed Vantx, Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralNorth Star Rx Llc2007-02-06Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralSt Marys Medical Park Pharmacy2014-02-05Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralPreferred Pharmaceuticals Inc.2016-07-25Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralProficient Rx LP2016-07-21Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralWest ward Pharmaceutical Corp2009-08-10Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralMajor Pharmaceuticals2013-05-15Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralAccord Healthcare, Inc.2015-10-01Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-12-18Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralMed Health Pharma, LLC2011-07-04Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralInternational Labs, Inc.2009-05-07Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralApotex Corp2007-02-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralTYA Pharmaceuticals2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralREMEDYREPACK INC.2014-03-17Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1Oralbryant ranch prepack2007-12-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralAmerican Health Packaging2011-04-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralMc Kesson Contract Packaging2011-09-27Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2012-02-17Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralPreferred Pharmaceuticals, Inc.2012-02-27Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions2007-02-062016-10-26Us
Sertraline HydrochlorideTablet, film coated100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralCobalt Laboratories Inc.2007-02-062016-11-18Us
Sertraline HydrochlorideTablet100 mg/1OralCamber Pharmaceuticals Inc.2007-10-18Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralUnit Dose Services2007-12-18Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralHikma Pharmaceutical2009-08-10Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralCardinal Health2007-02-01Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralAurobindo Pharma Limited2007-02-06Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralA S Medication Solutions2007-10-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-21Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralMylan Institutional Inc.2012-08-06Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralAurolife Pharma LLC2011-03-15Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralAphena Pharma Solutions Tennessee, Inc.2012-02-03Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralH.J. Harkins Company Inc.2007-12-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralCipla USA Inc.2016-07-21Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralPreferred Pharmaceuticals Inc.2016-11-21Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralMylan Pharmaceuticals Inc.2013-05-18Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-02-152016-10-13Us
Sertraline HydrochlorideTablet50 mg/1OralMedsource Pharmaceuticals2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralClinical Solutions Wholesale2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, coated150 mg/1OralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralMed Vantx, Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralCipla Limited2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralNorth Star Rx Llc2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralAphena Pharma Solutions Tennessee, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralSt Marys Medical Park Pharmacy2016-04-01Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralWest ward Pharmaceutical Corp2009-08-10Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralMajor Pharmaceuticals2013-05-15Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralAccord Healthcare, Inc.2015-10-01Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2007-12-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralCardinal Health2007-12-182016-03-11Us
Sertraline HydrochlorideTablet, film coated100 mg/1OralApotex Corp2007-02-06Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralTYA Pharmaceuticals2007-10-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralKeltman Pharmaceuticals Inc.2011-09-09Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralHikma Pharmaceutical2009-08-10Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1Oralbryant ranch prepack2007-09-05Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralAmerican Health Packaging2010-12-15Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralMc Kesson Contract Packaging2011-09-27Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralREMEDYREPACK INC.2012-08-27Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralPreferred Pharmaceuticals, Inc.2012-02-27Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralSTAT Rx USA LLC2007-12-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralUnit Dose Services2007-12-18Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralH.J. Harkins Company Inc.2007-12-18Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralCardinal Health2007-02-01Not applicableUs
Sertraline HydrochlorideTablet, coated25 mg/1OralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralAurobindo Pharma Limited2007-02-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2014-02-10Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-21Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralAurolife Pharma LLC2011-03-15Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-02-06Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralCipla USA Inc.2016-07-21Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralCobalt Laboratories Inc.2007-02-062016-11-18Us
Sertraline HydrochlorideTablet25 mg/1OralCamber Pharmaceuticals Inc.2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralREMEDYREPACK INC.2011-03-28Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralClinical Solutions Wholesale2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, coated200 mg/1OralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralMed Vantx, Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralCipla Limited2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralNorth Star Rx Llc2007-02-06Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2016-05-19Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralMylan Institutional Inc.2012-08-06Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralWest ward Pharmaceutical Corp2009-08-10Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralMajor Pharmaceuticals2013-05-15Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralAccord Healthcare, Inc.2015-10-01Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralLake Erie Medical DBA Quality Care Products LLC2007-01-02Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralCardinal Health2007-12-182016-03-11Us
Sertraline HydrochlorideTablet25 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralSTAT Rx USA LLC2007-12-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralAidarex Pharmaceuticals LLC2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralMed Health Pharma, LLC2011-07-04Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralInternational Labs, Inc.2009-05-12Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralHikma Pharmaceutical2009-08-10Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-12-01Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralMc Kesson Contract Packaging2011-09-27Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2012-10-23Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2016-10-21Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralMylan Pharmaceuticals Inc.2013-05-29Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralTorrent Pharmaceuticals Limited2007-09-05Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralREMEDYREPACK INC.2013-02-282016-10-13Us
Sertraline HydrochlorideTablet, film coated50 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralCardinal Health2007-02-01Not applicableUs
Sertraline HydrochlorideTablet, coated50 mg/1OralRanbaxy Pharmaceuticals Inc.2007-02-06Not applicableUs
Sertraline HydrochlorideSolution, concentrate20 mg/mLOralAurobindo Pharma Limited2008-10-31Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideSolution20 mg/mLOralNorth Star Rx Llc2008-10-31Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralSt Marys Medical Park Pharmacy2014-02-05Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralPreferred Pharmaceuticals Inc.2016-06-28Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralREMEDYREPACK INC.2016-11-14Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralCipla Limited2007-02-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralREMEDYREPACK INC.2012-01-19Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralPreferred Pharmaceuticals, Inc.2013-03-25Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralCipla USA Inc.2016-07-21Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralAidarex Pharmaceuticals LLC2016-07-21Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralCobalt Laboratories Inc.2007-02-062016-11-18Us
Sertraline HydrochlorideTablet50 mg/1OralCamber Pharmaceuticals Inc.2007-10-18Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralUnit Dose Services2007-12-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
Sertraline HydrochlorideTablet100 mg/1Oralbryant ranch prepack2007-12-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralAmerican Health Packaging2010-12-16Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralAurobindo Pharma Limited2007-02-06Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralLegacy Pharmaceutical Packaging, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-07-21Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralMylan Institutional Inc.2012-08-06Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralAurolife Pharma LLC2011-03-15Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralRebel Distributors Corp2009-07-01Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralPd Rx Pharmaceuticals, Inc.2009-08-10Not applicableUs
Sertraline HydrochlorideTablet25 mg/1OralH.J. Harkins Company Inc.2007-12-18Not applicableUs
Sertraline HydrochlorideTablet100 mg/1OralCardinal Health2007-12-182016-03-11Us
Sertraline HydrochlorideTablet25 mg/1OralSTAT Rx USA LLC2007-12-18Not applicableUs
Sertraline HydrochlorideTablet, film coated50 mg/1OralMed Health Pharma, LLC2011-07-04Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralInternational Labs, Inc.2009-05-10Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralApotex Corp2007-02-06Not applicableUs
Sertraline HydrochlorideTablet, film coated100 mg/1OralREMEDYREPACK INC.2014-02-26Not applicableUs
Sertraline HydrochlorideTablet50 mg/1OralClinical Solutions Wholesale, Llc2007-10-18Not applicableUs
Sertraline HydrochlorideTablet, film coated25 mg/1OralA S Medication Solutions2007-02-06Not applicableUs
Sertraline Hydrochloride TabletsTablet, film coated25 mg/1OralMajor Pharmaceuticals2009-11-10Not applicableUs
Sertraline Hydrochloride TabletsTablet, film coated50 mg/1OralMajor Pharmaceuticals2009-11-10Not applicableUs
Sertraline Hydrochloride TabletsTablet, film coated100 mg/1OralMajor Pharmaceuticals2009-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LustralNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sertraline Hydrochloride
Thumb
  • InChI Key: BLFQGGGGFNSJKA-XHXSRVRCSA-N
  • Monoisotopic Mass: 341.050482702
  • Average Mass: 342.691
DBSALT000808
Categories
UNIIQUC7NX6WMB
CAS number79617-96-2
WeightAverage: 306.23
Monoisotopic: 305.073804963
Chemical FormulaC17H17Cl2N
InChI KeyVGKDLMBJGBXTGI-SJCJKPOMSA-N
InChI
InChI=1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
IUPAC Name
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
SMILES
CN[[email protected]]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C2=CC=CC=C12
Pharmacology
IndicationFor the management of major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder with or without agoraphobia, premenstrual dysphoric disorder, social phobia, premature ejaculation, and vascular headaches.
Structured Indications
PharmacodynamicsSertraline, an antidepressant drug similar to citalopram, fluoxetine, and paroxetine, is of the selective serotonin reuptake inhibitor (SSRI) type. Sertraline has one active metabolite and, like the other SSRIs, have less sedative, anticholinergic, and cardiovascular effects than the tricyclic antidepressant drugs because it does not have clinically important anticholinergic, antihistamine, or adrenergic blocking activity.
Mechanism of actionThe exact mechanism of action sertraline is not fully known, but the drug appears to selectively inhibit the reuptake of serotonin at the presynaptic membrane. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission. It is suggested that these modifications are responsible for the antidepressant action observed during long term administration of antidepressants. It has also been hypothesized that obsessive-compulsive disorder is caused by the dysregulation of serotonin, as it is treated by sertraline, and the drug corrects this imbalance.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent dopamine transporterProteinunknown
inhibitor
HumanQ01959 details
Related Articles
AbsorptionThe effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food.
Volume of distributionNot Available
Protein binding98% bound to serum proteins, principally to albumin and α1-acid glycoprotein
Metabolism

Extensively metabolized in the liver. Sertraline metabolism involves N-demethylation, N-hydroxylation, oxidative deamination, and glucuronidation of sertraline carbamic acid. Sertraline undergoes N-demethylation primarily catalyzed by cytochrome P450 (CYP) 2B6, with CYP2C19, CYP3A4 and CYP2D6 contributing to a lesser extent. Deamination occurs via CYP3A4 and CYP2C19. In vitro studies have shown that monoamine oxidase A and B may also catalyze sertraline deamination. Sertraline N-carbamoyl glucuronidation has also been observed in human liver microsomes.

SubstrateEnzymesProduct
Sertraline
norsertralineDetails
Route of eliminationSertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination.
Half lifeThe elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours.
ClearanceNot Available
ToxicitySymptoms of toxicity include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome. The most frequently observed side effects include: GI effects such as nausea, diarrhea or loose stools, dyspepsia, and dry mouth; nervous system effects such as somnolence, dizziness, insomnia, and tremor; sexual dysfunction in males (principally ejaculatory delay); and sweating.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Sertraline.Investigational
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Sertraline.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Sertraline.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Sertraline.Experimental
AbirateroneThe serum concentration of Sertraline can be increased when it is combined with Abiraterone.Approved
AcarboseSertraline may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Sertraline.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be decreased when combined with Sertraline.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Sertraline.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Sertraline.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Acetophenazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Sertraline.Approved
Acetylsalicylic acidSertraline may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Sertraline.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Sertraline.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Sertraline.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Sertraline.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Sertraline.Approved
AlbiglutideSertraline may increase the hypoglycemic activities of Albiglutide.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Sertraline.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Sertraline.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Sertraline.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Sertraline.Approved, Vet Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Sertraline.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Sertraline.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Sertraline.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Sertraline.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sertraline.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Sertraline.Approved, Withdrawn
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Sertraline.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amineptine.Illicit, Withdrawn
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Sertraline.Approved, Withdrawn
AmiodaroneThe metabolism of Sertraline can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Sertraline is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Sertraline.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Sertraline.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Sertraline.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Sertraline is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Sertraline.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Sertraline.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Sertraline.Approved
AnagrelideSertraline may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Sertraline.Approved
Aop200704The serum concentration of Aop200704 can be increased when it is combined with Sertraline.Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Sertraline.Approved
AprepitantThe serum concentration of Sertraline can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Sertraline.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Sertraline.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Sertraline is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Sertraline can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Sertraline.Approved
Arsenic trioxideSertraline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherSertraline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Sertraline.Approved
AsenapineSertraline may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Sertraline.Approved, Withdrawn
AtazanavirThe metabolism of Sertraline can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Sertraline.Approved
AtomoxetineThe metabolism of Sertraline can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Sertraline.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Sertraline is combined with Azaperone.Vet Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Sertraline.Approved
AzithromycinSertraline may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Sertraline.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Sertraline.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Sertraline.Illicit
BedaquilineSertraline may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololThe serum concentration of Befunolol can be increased when it is combined with Sertraline.Experimental
BendroflumethiazideSertraline may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Sertraline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Sertraline is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Sertraline.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sertraline.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Sertraline.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Sertraline.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Sertraline.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Sertraline.Approved, Vet Approved
BetaxololThe metabolism of Sertraline can be decreased when combined with Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Sertraline.Approved
BexaroteneThe serum concentration of Sertraline can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Sertraline.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Sertraline is combined with Bifeprunox.Investigational
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Sertraline.Approved
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Sertraline.Investigational
BoceprevirThe metabolism of Sertraline can be decreased when combined with Boceprevir.Approved
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Sertraline.Approved
BortezomibThe metabolism of Sertraline can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sertraline can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Sertraline.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Sertraline.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Sertraline.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Sertraline.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Sertraline.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Sertraline is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Sertraline is combined with Bromperidol.Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Sertraline.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Sertraline.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be increased when it is combined with Sertraline.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Sertraline.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Sertraline.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Sertraline.Approved
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Sertraline.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be increased when it is combined with Sertraline.Approved
BuspironeBuspirone may increase the serotonergic activities of Sertraline.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sertraline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Sertraline.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Sertraline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Sertraline.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Sertraline.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Sertraline.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Sertraline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Sertraline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Sertraline.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Sertraline.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Sertraline.Approved
CapecitabineThe metabolism of Sertraline can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Sertraline.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Sertraline.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Sertraline.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Sertraline.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Sertraline.Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Sertraline.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Sertraline.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Sertraline.Withdrawn
CarteololThe metabolism of Carteolol can be decreased when combined with Sertraline.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Sertraline.Approved, Investigational
CelecoxibSertraline may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Sertraline.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Sertraline.Approved, Vet Approved
CeritinibThe serum concentration of Sertraline can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Sertraline.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Sertraline.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Sertraline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Sertraline.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Sertraline can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Sertraline.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Sertraline.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertraline.Approved
ChloroquineSertraline may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideSertraline may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Sertraline.Approved
ChlorpromazineSertraline may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Sertraline.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sertraline is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneSertraline may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Sertraline.Approved
CholecalciferolThe metabolism of Sertraline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Sertraline.Approved
CimetidineThe metabolism of Sertraline can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Sertraline can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sertraline.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Sertraline.Approved
CiprofloxacinSertraline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideSertraline may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Sertraline.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Sertraline.Approved
ClarithromycinThe metabolism of Sertraline can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sertraline can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Sertraline.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Sertraline.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Sertraline.Approved, Illicit
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Sertraline.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Sertraline.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Sertraline is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Sertraline.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Sertraline.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Sertraline resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sertraline.Approved, Illicit
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Sertraline.Approved, Illicit
ClotrimazoleThe metabolism of Sertraline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Sertraline.Approved
CobicistatThe serum concentration of Sertraline can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Sertraline.Approved
CocaineThe metabolism of Sertraline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Sertraline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Sertraline.Approved
ConivaptanThe serum concentration of Sertraline can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Sertraline.Approved
CrizotinibSertraline may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Sertraline.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Sertraline is combined with Cyclobenzaprine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Sertraline.Approved, Investigational
CyclosporineThe metabolism of Sertraline can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Sertraline can be decreased when used in combination with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Sertraline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Sertraline.Approved
DabrafenibThe serum concentration of Sertraline can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Sertraline.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Sertraline.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Sertraline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sertraline.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Sertraline.Approved, Investigational
DarifenacinThe metabolism of Sertraline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Sertraline can be decreased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Sertraline.Approved
DasatinibThe serum concentration of Sertraline can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Sertraline.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Sertraline.Approved
DeferasiroxThe serum concentration of Sertraline can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sertraline can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Sertraline.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sertraline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Sertraline.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Sertraline is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Sertraline is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Sertraline.Vet Approved
DexamethasoneThe serum concentration of Sertraline can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Sertraline.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Sertraline.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertraline.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Sertraline.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Sertraline.Approved, Illicit
DextromethorphanSertraline may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Sertraline.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Sertraline.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Sertraline.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Sertraline.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Sertraline.Approved, Vet Approved
DicoumarolSertraline may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Sertraline.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Sertraline.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Sertraline.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Sertraline.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Sertraline.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sertraline.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Sertraline.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Sertraline.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Sertraline.Illicit
DiltiazemThe metabolism of Sertraline can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Sertraline.Approved
DiphenhydramineThe metabolism of Sertraline can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Sertraline.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Sertraline.Approved
DisopyramideSertraline may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe risk or severity of adverse effects can be increased when Disulfiram is combined with Sertraline.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Sertraline.Approved, Investigational
DofetilideSertraline may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronSertraline may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneSertraline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Sertraline.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Sertraline.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Sertraline.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Sertraline.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Sertraline.Approved
DoxepinThe risk or severity of adverse effects can be increased when Sertraline is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Sertraline.Approved, Investigational
DoxycyclineThe metabolism of Sertraline can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Sertraline.Investigational
DronabinolThe metabolism of Dronabinol can be decreased when combined with Sertraline.Approved, Illicit
DronedaroneSertraline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolSertraline may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Sertraline.Experimental, Illicit
DulaglutideSertraline may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Sertraline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sertraline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Sertraline.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Sertraline.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Sertraline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Sertraline.Approved
EfavirenzThe serum concentration of Sertraline can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Sertraline.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Sertraline.Approved
EmpagliflozinSertraline may increase the hypoglycemic activities of Empagliflozin.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Sertraline.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Sertraline.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sertraline.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Sertraline.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Sertraline.Approved, Investigational
EnzalutamideThe serum concentration of Sertraline can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Sertraline.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Sertraline.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Sertraline is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Sertraline.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Sertraline.Approved, Investigational
ErythromycinThe risk or severity of adverse effects can be increased when Erythromycin is combined with Sertraline.Approved, Vet Approved
ErythromycinSertraline may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramSertraline may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Sertraline can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Sertraline is combined with Esmirtazapine.Investigational
EsmololThe serum concentration of Esmolol can be increased when it is combined with Sertraline.Approved
EsomeprazoleThe metabolism of Sertraline can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sertraline.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Sertraline.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Sertraline.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Sertraline.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sertraline.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Sertraline.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sertraline.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Sertraline.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline.Approved
Ethyl biscoumacetateSertraline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Sertraline.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sertraline.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Sertraline.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Sertraline.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Sertraline.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Sertraline.Approved
EtodolacSertraline may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.Approved
EtoperidoneSertraline may increase the serotonergic activities of Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Sertraline.Approved
EtoricoxibSertraline may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Sertraline.Illicit, Vet Approved
EtravirineThe serum concentration of Sertraline can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Sertraline.Approved
ExenatideSertraline may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Sertraline.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Sertraline.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Sertraline.Approved
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Sertraline.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Sertraline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineSertraline may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sertraline.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Sertraline.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Sertraline.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Sertraline.Approved, Investigational
FlecainideSertraline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Sertraline.Approved
FloxuridineThe metabolism of Sertraline can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Sertraline can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline.Approved, Illicit
FluindioneSertraline may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Sertraline.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Sertraline.Approved, Illicit
FluorouracilThe metabolism of Sertraline can be decreased when combined with Fluorouracil.Approved
FluoxetineSertraline may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolSertraline may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Sertraline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sertraline.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Sertraline is combined with Fluspirilene.Approved
FlutamideThe metabolism of Flutamide can be decreased when combined with Sertraline.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Sertraline.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Sertraline.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Sertraline.Approved
FluvoxamineThe metabolism of Sertraline can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Sertraline.Approved, Investigational
FosamprenavirThe metabolism of Sertraline can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sertraline can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Sertraline can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Sertraline.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Sertraline.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Sertraline.Approved, Vet Approved
Fusidic AcidThe serum concentration of Sertraline can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sertraline.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Sertraline.Approved
Gadobenic acidSertraline may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Sertraline.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Sertraline.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Sertraline.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Sertraline.Approved
GemfibrozilThe metabolism of Sertraline can be decreased when combined with Gemfibrozil.Approved
GemifloxacinSertraline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Sertraline.Investigational
GliclazideThe metabolism of Gliclazide can be decreased when combined with Sertraline.Approved
GlimepirideSertraline may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideSertraline may increase the hypoglycemic activities of Glipizide.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Sertraline.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Sertraline.Approved, Illicit
GlyburideThe metabolism of Glyburide can be decreased when combined with Sertraline.Approved
GoserelinSertraline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronSertraline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Sertraline.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Sertraline.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Sertraline.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Sertraline.Approved, Illicit, Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Sertraline.Approved
HaloperidolSertraline may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Sertraline.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Sertraline.Approved, Illicit
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Sertraline.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Sertraline.Approved
HydrochlorothiazideSertraline may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Sertraline.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Sertraline.Approved, Vet Approved
HydroflumethiazideSertraline may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Sertraline.Approved, Illicit
HydroxyzineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Sertraline.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Sertraline.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Sertraline.Approved
IbutilideSertraline may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Sertraline.Approved
IdelalisibThe serum concentration of Sertraline can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Sertraline.Approved
IloperidoneSertraline may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Sertraline can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Sertraline is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Sertraline.Approved
IndalpineSertraline may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideSertraline may increase the hyponatremic activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be increased when it is combined with Sertraline.Withdrawn
IndinavirThe metabolism of Sertraline can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Sertraline.Approved, Investigational
Insulin AspartSertraline may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSertraline may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineSertraline may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineSertraline may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanSertraline may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproSertraline may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Sertraline.Approved
Ioflupane I-123Sertraline may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Sertraline.Approved
IproclozideIproclozide may increase the serotonergic activities of Sertraline.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Sertraline.Withdrawn
IrbesartanThe metabolism of Sertraline can be decreased when combined with Irbesartan.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Sertraline.Approved, Investigational
IsavuconazoniumThe metabolism of Sertraline can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Sertraline.Approved
IsofluraneThe metabolism of Isoflurane can be decreased when combined with Sertraline.Approved, Vet Approved
IsoniazidThe metabolism of Sertraline can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Sertraline can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sertraline can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sertraline can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Sertraline.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Sertraline.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Sertraline.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Sertraline.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Sertraline.Approved
KetoconazoleThe metabolism of Sertraline can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Sertraline.Approved, Nutraceutical
LabetalolThe metabolism of Labetalol can be decreased when combined with Sertraline.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Sertraline.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Sertraline.Approved, Investigational
LanreotideSertraline may increase the hypoglycemic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Sertraline.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Sertraline.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Sertraline.Approved
LeflunomideThe metabolism of Sertraline can be decreased when combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Sertraline.Approved
LenvatinibSertraline may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideSertraline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Sertraline.Approved, Investigational
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Sertraline.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sertraline.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Sertraline.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Sertraline.Approved
LevodopaThe metabolism of Levodopa can be decreased when combined with Sertraline.Approved
LevofloxacinSertraline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Sertraline.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Sertraline is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Sertraline.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Sertraline.Approved
LidocaineThe metabolism of Sertraline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Sertraline.Approved
LinezolidLinezolid may increase the serotonergic activities of Sertraline.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Sertraline.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Sertraline.Approved
LiraglutideSertraline may increase the hypoglycemic activities of Liraglutide.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Sertraline.Approved
LithiumLithium may increase the serotonergic activities of Sertraline.Approved
LofentanilLofentanil may increase the serotonergic activities of Sertraline.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Sertraline.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Sertraline.Approved
LopinavirThe metabolism of Sertraline can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Sertraline.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sertraline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Sertraline is combined with Lorcaserin.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Sertraline.Approved
LovastatinThe metabolism of Sertraline can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Sertraline is combined with Loxapine.Approved
Lu AA21004Sertraline may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Sertraline can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sertraline can be decreased when it is combined with Lumacaftor.Approved
LumefantrineSertraline may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibSertraline may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Sertraline is combined with Lurasidone.Approved
MacitentanThe metabolism of Macitentan can be decreased when combined with Sertraline.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Sertraline.Approved, Vet Approved
MalathionThe metabolism of Malathion can be decreased when combined with Sertraline.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Sertraline.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.Approved
MebanazineMebanazine may increase the serotonergic activities of Sertraline.Withdrawn
MecaserminSertraline may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Sertraline.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Sertraline.Vet Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Sertraline.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Sertraline is combined with Melperone.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Sertraline.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sertraline.Approved, Vet Approved
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Sertraline.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Sertraline.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Sertraline.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline.Approved
MetforminSertraline may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Sertraline.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Sertraline.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Sertraline.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertraline.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Sertraline.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertraline.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertraline.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Sertraline.Approved
MethotrimeprazineThe metabolism of Sertraline can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Sertraline.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Sertraline.Approved
MethyclothiazideSertraline may increase the hyponatremic activities of Methyclothiazide.Approved
Methylene blueSertraline may increase the serotonergic activities of Methylene blue.Investigational
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Sertraline.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Sertraline.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Sertraline.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Sertraline.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Sertraline.Approved, Illicit, Withdrawn
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Sertraline.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertraline.Approved, Investigational
MetolazoneSertraline may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Sertraline.Approved, Investigational
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Sertraline.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Sertraline.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Sertraline.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Sertraline.Approved, Illicit
MifepristoneThe serum concentration of Sertraline can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolSertraline may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Sertraline is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Sertraline.Approved
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Sertraline.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Sertraline is combined with Mirtazapine.Approved
MitotaneThe serum concentration of Sertraline can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Sertraline.Approved, Investigational
MoclobemideMoclobemide may increase the serotonergic activities of Sertraline.Approved
ModafinilThe serum concentration of Sertraline can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Sertraline is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Sertraline.Approved, Withdrawn
MorphineThe serum concentration of Morphine can be increased when it is combined with Sertraline.Approved, Investigational
MoxifloxacinSertraline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sertraline.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Sertraline.Approved, Investigational
NabumetoneSertraline may increase the antiplatelet activities of Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Sertraline.Approved
NafcillinThe serum concentration of Sertraline can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Sertraline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Sertraline.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Sertraline.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Sertraline.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Sertraline.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Sertraline.Approved, Investigational
NefazodoneThe metabolism of Sertraline can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sertraline can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Sertraline can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sertraline can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Sertraline.Withdrawn
NicardipineThe metabolism of Sertraline can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Sertraline.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Sertraline.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Sertraline.Approved
NilotinibSertraline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Sertraline.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Sertraline.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Sertraline.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Sertraline.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Sertraline.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Sertraline.Approved
NormethadoneNormethadone may increase the serotonergic activities of Sertraline.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sertraline is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Sertraline.Withdrawn
OctreotideSertraline may increase the hypoglycemic activities of Octreotide.Approved, Investigational
OfloxacinSertraline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineSertraline may increase the serotonergic activities of Olanzapine.Approved, Investigational
OlaparibThe metabolism of Sertraline can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sertraline.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Sertraline.Approved
OmeprazoleThe metabolism of Sertraline can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronSertraline may increase the QTc-prolonging activities of Ondansetron.Approved
OpipramolThe risk or severity of adverse effects can be increased when Sertraline is combined with Opipramol.Investigational
OpiumOpium may increase the serotonergic activities of Sertraline.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Sertraline.Approved
OsanetantThe risk or severity of adverse effects can be increased when Sertraline is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Sertraline can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Sertraline.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertraline.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Sertraline.Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Sertraline.Approved
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Sertraline.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sertraline.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Sertraline.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Sertraline.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Sertraline.Approved, Vet Approved
PalbociclibThe serum concentration of Sertraline can be increased when it is combined with Palbociclib.Approved
PaliperidoneSertraline may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Sertraline.Approved, Investigational
PanobinostatThe serum concentration of Sertraline can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Sertraline can be decreased when combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Sertraline.Approved
ParecoxibSertraline may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Sertraline.Approved
ParoxetineThe metabolism of Sertraline can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideSertraline may increase the hypoglycemic activities of Pasireotide.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Sertraline.Approved
Peginterferon alfa-2bThe serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Sertraline.Approved, Investigational
PentamidineSertraline may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocinePentazocine may increase the serotonergic activities of Sertraline.Approved, Vet Approved
PentobarbitalThe metabolism of Sertraline can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Sertraline.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Sertraline.Investigational
PerflutrenSertraline may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Sertraline.Approved
PermethrinThe metabolism of Permethrin can be decreased when combined with Sertraline.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Sertraline is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Sertraline.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sertraline.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Sertraline.Withdrawn
PhenelzinePhenelzine may increase the serotonergic activities of Sertraline.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Sertraline.Approved, Withdrawn
PhenindioneSertraline may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Sertraline.Withdrawn
PhenobarbitalThe metabolism of Sertraline can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Sertraline.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Sertraline.Withdrawn
PhenprocoumonSertraline may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Sertraline.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Sertraline is combined with Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Sertraline.Approved
PioglitazoneSertraline may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Sertraline is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Sertraline.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Sertraline.Approved
PiritramidePiritramide may increase the serotonergic activities of Sertraline.Investigational
PirlindolePirlindole may increase the serotonergic activities of Sertraline.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Sertraline.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Sertraline.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Sertraline.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Sertraline.Approved
PolythiazideSertraline may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Sertraline.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Sertraline.Approved
PosaconazoleThe metabolism of Sertraline can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololThe serum concentration of Practolol can be increased when it is combined with Sertraline.Approved
PramlintideSertraline may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Sertraline.Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Sertraline.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Sertraline.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Sertraline.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Sertraline.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Sertraline.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Sertraline.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sertraline.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Sertraline.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Sertraline.Approved
PrimaquineSertraline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Sertraline can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideSertraline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Sertraline.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Procarbazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Sertraline.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Sertraline.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Sertraline.Approved
PromazineSertraline may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Sertraline.Approved
PropafenoneSertraline may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sertraline.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Sertraline.Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Sertraline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Sertraline.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Sertraline.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Sertraline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Sertraline is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Sertraline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Sertraline.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Sertraline.Approved
PyrimethamineThe metabolism of Sertraline can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Sertraline can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineSertraline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneSertraline may increase the hyponatremic activities of Quinethazone.Approved
QuinidineSertraline may increase the QTc-prolonging activities of Quinidine.Approved
QuinineSertraline may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Sertraline.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Sertraline is combined with Raclopride.Investigational
RamelteonThe metabolism of Ramelteon can be decreased when combined with Sertraline.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Sertraline.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Sertraline.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Sertraline.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Sertraline.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Sertraline.Approved, Withdrawn
RepaglinideSertraline may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
repinotanThe metabolism of repinotan can be decreased when combined with Sertraline.Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Sertraline.Approved
RifabutinThe metabolism of Sertraline can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sertraline can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sertraline can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Sertraline.Approved, Investigational
RisperidoneThe metabolism of Risperidone can be decreased when combined with Sertraline.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Sertraline is combined with Ritanserin.Investigational
RitonavirThe metabolism of Sertraline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Sertraline.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Sertraline.Approved
RofecoxibSertraline may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Sertraline can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Sertraline.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Sertraline.Vet Approved
RopiniroleThe metabolism of Sertraline can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Sertraline.Approved
RosiglitazoneSertraline may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Sertraline.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Sertraline.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Sertraline.Experimental
SafrazineSafrazine may increase the serotonergic activities of Sertraline.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Sertraline.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Sertraline.Approved, Vet Approved
SaquinavirThe metabolism of Sertraline can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinSertraline may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline.Approved
SecobarbitalThe metabolism of Sertraline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Sertraline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Sertraline.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Sertraline.Approved, Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Sertraline.Approved, Withdrawn
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Sertraline.Approved, Vet Approved
SildenafilThe metabolism of Sertraline can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Sertraline.Approved
SiltuximabThe serum concentration of Sertraline can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sertraline can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Sertraline.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Sertraline.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Sertraline.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Sertraline.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Sertraline.Approved, Investigational
SotalolSertraline may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Sertraline.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Sertraline.Experimental
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Sertraline.Experimental
St. John's WortThe serum concentration of Sertraline can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sertraline can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Sertraline.Approved, Investigational
SulfadiazineThe metabolism of Sertraline can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sertraline can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Sertraline can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sertraline is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Sertraline.Approved, Investigational
SunitinibSertraline may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Sertraline.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Sertraline.Approved, Investigational
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Sertraline.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Sertraline resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Sertraline.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Sertraline.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Sertraline is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Sertraline.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Sertraline.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Sertraline.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Sertraline.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Sertraline.Investigational, Withdrawn
TelaprevirThe metabolism of Sertraline can be decreased when combined with Telaprevir.Approved
TelavancinSertraline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Sertraline can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Sertraline.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Sertraline.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Sertraline.Approved
TenofovirThe metabolism of Sertraline can be decreased when combined with Tenofovir.Approved, Investigational
TerbinafineThe metabolism of Sertraline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Sertraline.Withdrawn
TeriflunomideThe serum concentration of Sertraline can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Sertraline.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Sertraline.Approved, Investigational
TetrabenazineSertraline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Sertraline.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Sertraline.Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Sertraline.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Sertraline can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertraline.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Sertraline.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sertraline.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Sertraline is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Sertraline.Approved
ThiotepaThe metabolism of Sertraline can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Sertraline is combined with Thiothixene.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Sertraline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Sertraline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Sertraline is combined with Tianeptine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Sertraline is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Sertraline.Approved
TiclopidineThe metabolism of Sertraline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Sertraline.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Sertraline.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Sertraline.Approved
TipranavirThe metabolism of Sertraline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Sertraline.Approved
TocilizumabThe serum concentration of Sertraline can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Sertraline.Approved, Investigational
TolazamideSertraline may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideThe metabolism of Sertraline can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Sertraline.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Sertraline.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Sertraline.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Sertraline.Approved
TopiramateThe metabolism of Sertraline can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Sertraline.Approved, Investigational
ToremifeneSertraline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Sertraline.Approved, Investigational
TramadolSertraline may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Sertraline.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Sertraline.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Sertraline.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sertraline.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Sertraline.Approved, Investigational, Nutraceutical
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sertraline.Approved
TrichlormethiazideSertraline may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline.Approved, Vet Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Sertraline.Approved
TrimethoprimThe metabolism of Sertraline can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Sertraline is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Sertraline.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Sertraline.Withdrawn
TropisetronTropisetron may increase the serotonergic activities of Sertraline.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Sertraline.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Sertraline.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Sertraline.Approved
ValdecoxibSertraline may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Sertraline.Approved, Investigational
ValsartanThe metabolism of Sertraline can be decreased when combined with Valsartan.Approved, Investigational
VandetanibSertraline may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Sertraline.Approved
VemurafenibThe serum concentration of Sertraline can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Sertraline.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Sertraline.Approved
VerapamilThe metabolism of Sertraline can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Sertraline.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Sertraline is combined with Vilazodone.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Sertraline.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Sertraline.Approved, Investigational
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Sertraline.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Sertraline.Approved
VoriconazoleThe metabolism of Sertraline can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Sertraline is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be decreased when combined with Sertraline.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Sertraline.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Sertraline.Approved, Vet Approved
ZafirlukastThe metabolism of Sertraline can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Sertraline.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Sertraline.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Sertraline.Approved
ZimelidineSertraline may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneSertraline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Sertraline.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sertraline.Approved, Investigational
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Sertraline.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Sertraline.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sertraline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Sertraline is combined with Zotepine.Approved
ZuclopenthixolSertraline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid St.John's Wort.
  • Avoid taking with grapefruit juice.
  • Take with food.
References
Synthesis Reference

George J. Quallich, Michael T. Williams, “Process for preparing sertraline intermediates.” U.S. Patent US4839104, issued February, 1977.

US4839104
General References
  1. Couzin J: The brains behind blockbusters. Science. 2005 Jul 29;309(5735):728. [PubMed:16051786 ]
  2. Fabre LF, Abuzzahab FS, Amin M, Claghorn JL, Mendels J, Petrie WM, Dube S, Small JG: Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995 Nov 1;38(9):592-602. [PubMed:8573661 ]
  3. Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, Landbloom R, Munjack D, Riesenberg R, Robinson D, Roy-Byrne P, Phillips K, Du Pont IJ: Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol. 1999 Apr;19(2):172-6. [PubMed:10211919 ]
  4. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA. 2000 Apr 12;283(14):1837-44. [PubMed:10770145 ]
  5. Yonkers KA, Halbreich U, Freeman E, Brown C, Endicott J, Frank E, Parry B, Pearlstein T, Severino S, Stout A, Stone A, Harrison W: Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA. 1997 Sep 24;278(12):983-8. [PubMed:9307345 ]
  6. Shelton RC: The role of sertraline in the management of depression. Clin Ther. 1994 Sep-Oct;16(5):768-82; discussion 767. [PubMed:7859236 ]
  7. Murdoch D, McTavish D: Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 1992 Oct;44(4):604-24. [PubMed:1281075 ]
External Links
ATC CodesN06AB06
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (98.7 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9713
Caco-2 permeable+0.6995
P-glycoprotein substrateNon-substrate0.5858
P-glycoprotein inhibitor IInhibitor0.7333
P-glycoprotein inhibitor IINon-inhibitor0.8319
Renal organic cation transporterNon-inhibitor0.6726
CYP450 2C9 substrateNon-substrate0.71
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6304
CYP450 1A2 substrateInhibitor0.7909
CYP450 2C9 inhibitorNon-inhibitor0.9307
CYP450 2D6 inhibitorNon-inhibitor0.6469
CYP450 2C19 inhibitorInhibitor0.6839
CYP450 3A4 inhibitorNon-inhibitor0.5442
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6633
Ames testAMES toxic0.5353
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.9522
Rat acute toxicity2.5020 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9151
hERG inhibition (predictor II)Inhibitor0.7185
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral100 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
SolutionOral20 mg/mL
Tablet, coatedOral100 mg/1
Tablet, coatedOral150 mg/1
Tablet, coatedOral200 mg/1
Tablet, coatedOral25 mg/1
Tablet, coatedOral50 mg/1
CapsuleOral100.0 mg
CapsuleOral25.0 mg
CapsuleOral50.0 mg
CapsuleOral25 mg
Solution, concentrateOral20 mg/mL
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
CapsuleOral100 mg
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
Sertraline hcl powder480.0USD g
Zoloft 20 mg/ml Concentrate 60ml Bottle94.75USD bottle
Sertraline HCl 20 mg/ml Concentrate 60ml Bottle66.85USD bottle
Zoloft 50 mg tablet4.02USD tablet
Zoloft 100 mg tablet3.94USD tablet
Zoloft 25 mg tablet3.94USD tablet
Sertraline hcl 100 mg tablet2.77USD tablet
Sertraline hcl 25 mg tablet2.77USD tablet
Sertraline hcl 50 mg tablet2.77USD tablet
Zoloft 100 mg Capsule1.9USD capsule
Zoloft 50 mg Capsule1.81USD capsule
Apo-Sertraline 100 mg Capsule1.06USD capsule
Co Sertraline 100 mg Capsule1.06USD capsule
Mylan-Sertraline 100 mg Capsule1.06USD capsule
Novo-Sertraline 100 mg Capsule1.06USD capsule
Phl-Sertraline 100 mg Capsule1.06USD capsule
Pms-Sertraline 100 mg Capsule1.06USD capsule
Ratio-Sertraline 100 mg Capsule1.06USD capsule
Sandoz Sertraline 100 mg Capsule1.06USD capsule
Sertraline 100 mg Capsule1.06USD capsule
Apo-Sertraline 50 mg Capsule1.01USD capsule
Co Sertraline 50 mg Capsule1.01USD capsule
Mylan-Sertraline 50 mg Capsule1.01USD capsule
Novo-Sertraline 50 mg Capsule1.01USD capsule
Phl-Sertraline 50 mg Capsule1.01USD capsule
Pms-Sertraline 50 mg Capsule1.01USD capsule
Ratio-Sertraline 50 mg Capsule1.01USD capsule
Sandoz Sertraline 50 mg Capsule1.01USD capsule
Sertraline 50 mg Capsule1.01USD capsule
Zoloft 25 mg Capsule0.91USD capsule
Apo-Sertraline 25 mg Capsule0.51USD capsule
Co Sertraline 25 mg Capsule0.51USD capsule
Mylan-Sertraline 25 mg Capsule0.51USD capsule
Novo-Sertraline 25 mg Capsule0.51USD capsule
Phl-Sertraline 25 mg Capsule0.51USD capsule
Pms-Sertraline 25 mg Capsule0.51USD capsule
Ratio-Sertraline 25 mg Capsule0.51USD capsule
Sandoz Sertraline 25 mg Capsule0.51USD capsule
Sertraline 25 mg Capsule0.51USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2029065 No1994-11-082010-10-31Canada
US4962128 No1992-11-022009-11-02Us
US6727283 Yes2000-04-112020-04-11Us
US7067555 Yes2000-04-112020-04-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point243-245 °CNot Available
water solubility3.5mg/LNot Available
logP5.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000145 mg/mLALOGPS
logP5.06ALOGPS
logP5.15ChemAxon
logS-6.3ALOGPS
pKa (Strongest Basic)9.85ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity85.74 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00b9-2890000000-d53a90b04ec8457ad2f1View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tametralines. These are compounds containing a tametraline moiety, which consists of a tetrahydronaphthalene linked to a phenyl group to form N-methyl-4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine skeleton.
KingdomOrganic compounds
Super ClassBenzenoids
ClassTetralins
Sub ClassTametralines
Direct ParentTametralines
Alternative Parents
Substituents
  • Tametraline
  • 1,2-dichlorobenzene
  • Aralkylamine
  • Halobenzene
  • Chlorobenzene
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Benmansour S, Cecchi M, Morilak DA, Gerhardt GA, Javors MA, Gould GG, Frazer A: Effects of chronic antidepressant treatments on serotonin transporter function, density, and mRNA level. J Neurosci. 1999 Dec 1;19(23):10494-501. [PubMed:10575045 ]
  2. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A: Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci. 2002 Aug 1;22(15):6766-72. [PubMed:12151556 ]
  3. Borkowska A, Pilaczynska E, Araszkiewicz A, Rybakowski J: [The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]. Psychiatr Pol. 2002 Nov-Dec;36(6 Suppl):289-95. [PubMed:12647451 ]
  4. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB: The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl). 2004 Aug;174(4):525-9. Epub 2003 Sep 4. [PubMed:12955294 ]
  5. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O: Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem. 2005 Jan;92(1):21-8. [PubMed:15606893 ]
  6. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  7. David DJ, Bourin M, Hascoet M, Colombel MC, Baker GB, Jolliet P: Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology (Berl). 2001 Feb;153(4):443-9. [PubMed:11243491 ]
  8. Rogoz Z, Skuza G: Mechanism of synergistic action following co-treatment with pramipexole and fluoxetine or sertraline in the forced swimming test in rats. Pharmacol Rep. 2006 Jul-Aug;58(4):493-500. [PubMed:16963794 ]
  9. Muneoka K, Shirayama Y, Takigawa M, Shioda S: Brain region-specific effects of short-term treatment with duloxetine, venlafaxine, milnacipran and sertraline on monoamine metabolism in rats. Neurochem Res. 2009 Mar;34(3):542-55. doi: 10.1007/s11064-008-9818-2. Epub 2008 Aug 27. [PubMed:18751896 ]
  10. Iehle C, Delos S, Filhol O, Martin PM: Baculovirus-directed expression of human prostatic steroid 5 alpha-reductase 1 in an active form. J Steroid Biochem Mol Biol. 1993 Aug;46(2):177-82. [PubMed:8664165 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
  2. Ghanizadeh A: Sertraline-associated hair loss. J Drugs Dermatol. 2008 Jul;7(7):693-4. [PubMed:18664165 ]
  3. Lemke MR: [Antidepressant effects of dopamine agonists. Experimental and clinical findings]. Nervenarzt. 2007 Jan;78(1):31-8. [PubMed:17187269 ]
  4. Nemeroff CB, Owens MJ: Pharmacologic differences among the SSRIs: focus on monoamine transporters and the HPA axis. CNS Spectr. 2004 Jun;9(6 Suppl 4):23-31. [PubMed:15181382 ]
  5. Goodnick PJ, Goldstein BJ: Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology. J Psychopharmacol. 1998;12(3 Suppl B):S5-20. [PubMed:9808077 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  3. DeVane CL, Donovan JL, Liston HL, Markowitz JS, Cheng KT, Risch SC, Willard L: Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol. 2004 Feb;24(1):4-10. [PubMed:14709940 ]
  4. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  3. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  4. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Rojdmark S, von Bahr C: [Metabolic interaction between psychopharmaceuticals. Probable cause of exacerbation of hypothyroidism according to a case report]. Lakartidningen. 2002 Jun 20;99(25):2854-6. [PubMed:12143142 ]
  3. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
  2. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Obach RS, Cox LM, Tremaine LM: Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos. 2005 Feb;33(2):262-70. Epub 2004 Nov 16. [PubMed:15547048 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Not Available
Gene Name:
CYP2B
Uniprot ID:
Q14097
Molecular Weight:
43147.81 Da
References
  1. Haduch A, Wojcikowski J, Daniel WA: Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study. Pharmacol Rep. 2008 Nov-Dec;60(6):957-65. [PubMed:19211989 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE: Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther. 2003 Apr;305(1):197-204. [PubMed:12649369 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54